Ask AI
ProCE Banner Activity

BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

Podcast Episodes

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP explore the latest key clinical updates on BTK inhibitors in CLL, featuring insights from the randomized phase III FLAIR, SEQUOIA, and BRUIN CLL-321 trials presented at ASCO and EHA 2025. This episode unpacks evolving treatment strategies, MRD-guided approaches, and what these developments mean for oncology professionals.

Released: July 25, 2025

Expiration: January 24, 2026

Share

Provided by

Provided by ProCE, LLC in collaboration with Clinical Care Options, LLC

ProCE Banner
ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Disclosure

Primary Author

James Davis, PharmD, BCOP: consultant/advisor/speaker: Bristol Myers Squibb, Janssen.

Victoria Nachar, PharmD, BCOP: consultant/advisor/speaker: BeiGene, Genmab, GlaxoSmithKline.